Compare ASTRAZENECA PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ALKEM LABORATORIES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ALKEM LABORATORIES ASTRAZENECA PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 93.0 - - View Chart
P/BV x 28.2 8.8 319.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ALKEM LABORATORIES
Mar-16
ASTRAZENECA PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2781,589 80.4%   
Low Rs8831,232 71.6%   
Sales per share (Unadj.) Rs228.4417.5 54.7%  
Earnings per share (Unadj.) Rs10.456.3 18.4%  
Cash flow per share (Unadj.) Rs16.364.7 25.1%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs98.8292.9 33.7%  
Shares outstanding (eoy) m25.00119.57 20.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.4 140.0%   
Avg P/E ratio x104.225.1 416.0%  
P/CF ratio (eoy) x66.421.8 304.8%  
Price / Book Value ratio x10.94.8 227.1%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m27,008168,653 16.0%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,5359,171 16.7%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,71049,915 11.4%  
Other income Rs m1231,645 7.4%   
Total revenues Rs m5,83351,561 11.3%   
Gross profit Rs m4638,482 5.5%  
Depreciation Rs m1471,006 14.7%   
Interest Rs m0671 0.0%   
Profit before tax Rs m4388,451 5.2%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,606 11.1%   
Profit after tax Rs m2596,731 3.8%  
Gross profit margin %8.117.0 47.7%  
Effective tax rate %40.819.0 214.9%   
Net profit margin %4.513.5 33.6%  
BALANCE SHEET DATA
Current assets Rs m3,20927,062 11.9%   
Current liabilities Rs m2,07015,324 13.5%   
Net working cap to sales %20.023.5 84.9%  
Current ratio x1.61.8 87.8%  
Inventory Days Days7267 108.8%  
Debtors Days Days3541 84.6%  
Net fixed assets Rs m79012,610 6.3%   
Share capital Rs m50239 20.9%   
"Free" reserves Rs m2,41934,490 7.0%   
Net worth Rs m2,46935,027 7.0%   
Long term debt Rs m01,212 0.0%   
Total assets Rs m4,60554,387 8.5%  
Interest coverage xNM13.6-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.9 135.1%   
Return on assets %5.613.6 41.3%  
Return on equity %10.519.2 54.6%  
Return on capital %17.724.9 71.4%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m3006,563 4.6%   
Fx outflow Rs m2,0153,012 66.9%   
Net fx Rs m-1,7153,552 -48.3%   
CASH FLOW
From Operations Rs m887,259 1.2%  
From Investments Rs m-941,864 -5.0%  
From Financial Activity Rs mNA-9,273 0.0%  
Net Cashflow Rs m-6-150 3.8%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 33.1 0.9%  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 0.0 -  
Shareholders   12,856 68,381 18.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

December Quarter Results, IPO Buzz, and Top Cues in Focus Today(Pre-Open)

On Friday, Indian share markets witnessed most of the selling pressure during closing hours and ended lower. The BSE Sensex closed lower by 202 points to end the day at 41,258.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Buy this 'Crorepati Stock' and You Could End Up Stinking Rich(Profit Hunter)

Feb 5, 2020

I'm talking about an individual small cap stock that could go up so many times that they make their investors stinking rich in the process. You definitely want to know more...

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Will Your Trade Go Up or Down Today?(Fast Profits Daily)

Feb 5, 2020

How you can find out which way your trade is likely to move on any given trading day.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

No Change in My Long-Term View on the Rebirth of India Stocks(The 5 Minute Wrapup)

Feb 6, 2020

Why the recent post budget volatility has not affected my bullish view on the Rebirth of India stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Feb 17, 2020 09:39 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS